Market Place
Sourcing Support
Nexalin Publishes Neuroimaging Data On Chronic Insomnia Therapy
28 Apr 2026 //
GLOBENEWSWIRE
Nexalin Progresses FDA Alzheimer`s Strategy Post Key Leadership
15 Apr 2026 //
GLOBENEWSWIRE
Nexalin Hosts Live Investor Webinar On April 21
14 Apr 2026 //
GLOBENEWSWIRE
Nexalin Study Reveals DIFS Tech Cuts Self-Injury, Depression
09 Apr 2026 //
GLOBENEWSWIRE
Nexalin Participates in and Commends Recent Momentum Supporting
23 Feb 2026 //
GLOBENEWSWIRE
Nexalin Launches NeuroCare for Alzheimer`s and Mood Disorders
05 Feb 2026 //
GLOBENEWSWIRE
Nexalin Showcases Leading DIFS Neuroimaging Research
02 Feb 2026 //
GLOBENEWSWIRE
Nexalin Technology Receives Nasdaq Listing Status Notification
23 Jan 2026 //
GLOBENEWSWIRE
Study Shows Nexalin`s DIFS Neurostimulation Enhances Attention
14 Jan 2026 //
GLOBENEWSWIRE
Nexalin Wraps FDA Q-Submission For Gen-2 SYNC Neurostimulation
03 Dec 2025 //
GLOBENEWSWIRE
Nexalin Technology Hosts Live Investor Webinar On December 4
02 Dec 2025 //
GLOBENEWSWIRE
Nexalin 15mA Device Aids Comorbid Gambling, Alcohol Treatment
18 Nov 2025 //
GLOBENEWSWIRE
Nexalin Technology Appoints Carmi Masha As Exclusive Distributor
13 Nov 2025 //
GLOBENEWSWIRE
Nexalin Gen-2 Sync Q-Submission Accepted By FDA For Alzheimer
05 Nov 2025 //
GLOBENEWSWIRE
Nexalin Tech Gets Approval To Sell Gen 2 SYNC, DIFS Device
30 Oct 2025 //
GLOBENEWSWIRE
Nexalin DIFS Tech Improves Cognition, Brain Network in Alzheimer
21 Oct 2025 //
GLOBENEWSWIRE
Nexalin Tech Appoints Dr. Robert Rothstein To Board
13 Oct 2025 //
GLOBENEWSWIRE
Nexalin Tech To Attend 2025 Maxim Growth Summit
10 Oct 2025 //
GLOBENEWSWIRE
Nexalin Tech Reports More Positive Results in Alzheimer Disease
08 Oct 2025 //
GLOBENEWSWIRE
Nexalin Tech Issues U.s. Patent For Halo™ Clarity Device
25 Sep 2025 //
GLOBENEWSWIRE
Nexalin Technology Hosts Live Investor Webinar on September 9
25 Aug 2025 //
GLOBENEWSWIRE
Nexalin Technology Names Justin Van Fleet Cfo for Growth Phase
01 Aug 2025 //
GLOBENEWSWIRE
Nexalin Technology`s Live Investor Webinar & Q&A on June 3
28 May 2025 //
GLOBENEWSWIRE
Nexalin Reforms Scientific Board to Advance Alzheimer’s Program
13 May 2025 //
GLOBENEWSWIRE
Nexalin Technology Closes $5.0M Public Offering
06 May 2025 //
GLOBENEWSWIRE
Nexalin Technology Prices $5.0M Public Offering of Common Stock
05 May 2025 //
GLOBENEWSWIRE
Nexalin Technology Starts FDA Q-Submission for Gen-2 SYNC
01 May 2025 //
GLOBENEWSWIRE
Nexalin Technology Gets IRB Approval in Brazil for Anxiety
24 Apr 2025 //
GLOBENEWSWIRE
Nexalin Completes Phases One-Five for HALO Clinical Research
23 Apr 2025 //
GLOBENEWSWIRE
Nexalin Supports Health Tech Act for AI-Enabled Devices
21 Apr 2025 //
GLOBENEWSWIRE
Nexalin Technology Secures USPTO Patent for DIFS Technology
14 Apr 2025 //
GLOBENEWSWIRE
Nexalin Technology Enrolls First Patients in UCSD Clinical Trial
02 Apr 2025 //
GLOBENEWSWIRE
Nexalin Technology`s Live Investor Webinar & Q&A on April 3
26 Mar 2025 //
GLOBENEWSWIRE
Nexalin Tech Gets USPTO Nod For DIFS Tech In Substance Use
03 Mar 2025 //
GLOBENEWSWIRE
Nexalin Begins Patient Recruitment For TBI & PTSD Study
28 Feb 2025 //
GLOBENEWSWIRE
Nexalin Technology Welcomes Gen. Wesley Clark to Advisory Board
26 Feb 2025 //
GLOBENEWSWIRE
Nexalin gets UCSD IRB Approval for HALO™for mTBI & PTSD
18 Feb 2025 //
GLOBENEWSWIRE
Nexalin Named Industry Co-Chair Of National TBI Coalition
10 Feb 2025 //
GLOBENEWSWIRE
Nexalin Technology Hosts Live Investor Webinar And Q&A Session
23 Jan 2025 //
GLOBENEWSWIRE
Nexalin CEO Shares 2025 Outlook, Highlights Recent Achievements
14 Jan 2025 //
GLOBENEWSWIRE
Nexalin Technology Completes Ph 1of its Innovative Virtual Clinic
23 Dec 2024 //
GLOBENEWSWIRE
Peer-Reviewed Study Validate Nexalin`s DIFS Technology in Neuromode
26 Nov 2024 //
GLOBENEWSWIRE
Nexalin Technology CEO Letter to Shareholders
11 Nov 2024 //
GLOBENEWSWIRE
Nexalin Technology Regains Nasdaq Listing Compliance
01 Nov 2024 //
GLOBENEWSWIRE
Nexalin Technology Hosts Live Investor Webinar on Nov 5
01 Nov 2024 //
GLOBENEWSWIRE
Nexalin Technology Study on Alzheimer’s Published in Journal
28 Oct 2024 //
#N/A
Nexalin Technology Plans Clinical Trial With Gen-3 Halo Headset
22 Oct 2024 //
GLOBENEWSWIRE
Study Shows Nexalin’s DIFS Improves Memory In Alzheimer’s Patients
17 Oct 2024 //
GLOBENEWSWIRE
Nexalin Technology Appoints Carolyn Shelton As Senior VP
14 Oct 2024 //
GLOBENEWSWIRE
Nexalin Participates In Roundtable On Virtual Opioid Treatment
05 Sep 2024 //
GLOBENEWSWIRE
Nexalin Joins Industry Coalition For Substance Use Recovery
18 Jul 2024 //
GLOBENEWSWIRE
Nexalin Technology Announces Closing of $5.2 Million Public Offering
01 Jul 2024 //
GLOBENEWSWIRE
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
27 Jun 2024 //
GLOBENEWSWIRE
Nexalin Technology Announces Positive Clinical Study Data in MDD in Journal
26 Jun 2024 //
GLOBENEWSWIRE
Nexalin Tech Awarded Patent For Non-Invasive Device For Alzheimer’s And Dementia
20 Jun 2024 //
GLOBENEWSWIRE
Nexalin Announces Approval to Sell Nexalin’s Neurostimulation Device by Anvisa
13 Jun 2024 //
GLOBENEWSWIRE
Nexalin Tech: Presenting At Spring MicroCap Rodeo On June 6
04 Jun 2024 //
GLOBENEWSWIRE
FDA Aligns On Nexalin`s HALO Anxiety, Insomnia Clinical Study Design
03 Jun 2024 //
GLOBENEWSWIRE
Nexalin Joins TBI Registry Coalition For Awareness, Research
22 May 2024 //
GLOBENEWSWIRE
Nexalin Live Investor Webinar And Q&A On May 23
09 May 2024 //
GLOBENEWSWIRE
